Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ContraFect nets $7.2M grant for antimicrobial candidate
July 2019
SHARING OPTIONS:

YONKERS, N.Y.—Early June featured an announcement from ContraFect Corp. that it had received $7.2 million in funding from the Congressionally Directed Medical Research Programs under the Military Infectious Diseases Research Program, United States Army Medical Research and Development Command. This funding, provided over the course of three years, will support ContraFect’s development of CF-296, its lysin candidate, through IND-enabling studies. Lysins are antimicrobial biologics with a unique mechanism of action that enables rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, according to a press release. Dr. Roger J. Pomerantz, chairman and CEO of ContraFect, said that the funding “further validates our novel therapeutic approach, using direct lytic agents, which are non-antibiotic anti-infective agents, as a new medical modality, following the compelling clinical data reported from our Phase 2 trial of exebacase in patients with Staph bacteremia.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.